Management tracks: Maze, Tiaki, NED, Annexon and more
By Jonathan Block, Associate Editor | Jul 10, 2019 | 10:58 PM GMT
Maze Therapeutics (Redwood City, Calif.) said Richard Scheller joined its board. Scheller, who in January became chairman of R&D at BridgeBio Pharma Inc. (NASDAQ:BBIO), was CSO and head of therapeutics at personal genetics company 23andMe Inc.
Read the full 366 word article
User Sign In
This article may not be distributed to non-subscribers
PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD